Tennessee Oncology

Summary

Tennessee Oncology is a medical facility located in Nashville, Tennessee. This center is recognized for care of Lung Cancer, Breast Cancer, Solid Tumors, Cancer, Non-Small Cell Lung Cancer and other specialties. Tennessee Oncology is involved with conducting 246 clinical trials across 229 conditions. There are 14 research doctors associated with this hospital, such as Melissa Johnson, MD, Erika P Hamilton, Meredith A McKean, and David R. Spigel, MD.

Top PIs

Clinical Trials running at Tennessee Oncology

Lung Cancer

Breast Cancer

Multiple Myeloma

Cancer

Pancreatic Cancer

Ovarian Cancer

Solid Tumors

Chronic Lymphocytic Leukemia

Lymphoma

Non-Small Cell Lung Cancer

MK-2870

for Non-Small Cell Lung Cancer

The purpose of this study is to evaluate sacituzumab tirumotecan versus chemotherapy (docetaxel or pemetrexed) for the treatment of previously-treated non-small cell lung cancer (NSCLC) with exon 19del or exon 21 L858R EGFR mutations (hereafter referred to as EGFR mutations or EGFR-mutated) or any of the follow genomic alterations: ALK gene rearrangements, ROS1 rearrangements, BRAF V600E mutations, NTRK gene fusions, MET exon 14 skipping mutations, RET rearrangements, or less common EGFR point mutations of exon 20 S768I, exon 21 L861Q, or exon 18 G719X mutations. The primary hypotheses are that sacituzumab tirumotecan is: (1) superior to chemotherapy with respect to progression-free survival (PFS) per RECIST 1.1 as assessed by BICR in NSCLC with EGFR mutations; and (2) superior to chemotherapy with respect to overall survival (OS) in NSCLC with EGFR mutations.

Recruiting

2 awards

Phase 3

9 criteria

LY3537982 + Immunotherapy/Chemotherapy

for Non-Small Cell Lung Cancer

This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.

Recruiting

1 award

Phase 3

14 criteria

Combination Therapy

for Lung Cancer

This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

Recruiting

1 award

Phase 2

17 criteria